|
Reliably identify the presence of aggregates in characterization of mAbs
Monoclonal
antibody (mAb) biotherapeutics have emerged as a critical class of
drugs. The efficacy and safety of these biotherapeutics are highly
dependent on maintaining a correct molecular structure. The presence of
aggregates can lead to undesirable consequences, such as loss of
therapeutic activity or even negative physiological effects. Identifying
the presence of aggregate proteins in biotherapeutics is crucial.
Nobody understands better than Agilent
A unique
non-destructive prescreening method using the Agilent Cary 60
UV-Vis spectrophotometer can quickly, easily, and reliably identify the
presence of aggregate proteins.
BE AGILENT SURE
|
|
 |
Featured Webinar:
How fab are your mAbs?
A complete aggregate analysis workflow for comprehensive, efficient, and reliable characterization of monoclonal antibodies
|
 |
New Application Note
Characterization of mAb Aggregation Using an
Agilent Cary 60 UV-Vis
and 1260 Infinity LC
|
|
